Alanna Weisman

Alanna Weisman

Auto-generated profile, based on publicly available information

Alanna Weisman

Lunenfeld‐Tanenbaum Research Institute Mount Sinai Hospital Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
AWAlanna Weisman
Alanna Weisman
JBJohnny-Wei Bai
Johnny-Wei Bai
MCMarina Cardinez
Marina Cardinez
CKCaroline K Kramer
Caroline K Kramer
BPBruce A Perkins
Bruce A Perkins

11 January 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
JLJulie A. Lovshin
Julie A. Lovshin
GBGeneviève Boulet
Geneviève Boulet
YLYuliya Lytvyn
Yuliya Lytvyn
LLLeif E. Lovblom
Leif E. Lovblom
PBPetter Bjornstad
Petter Bjornstad
DCDavid Z.I. Cherney
David Z.I. Cherney
BACKGROUND. In type 1 diabetes (T1D), adjuvant treatment with inhibitors of the renin-angiotensin-aldosterone system (RAAS), which dilate the efferent arteriole, is associated with prevention of progressive albuminuria and renal dysfunction. Uncertainty still exists as to why some individuals with long-standing T1D develop diabetic kidney disease (DKD) while others do not (DKD resistors). We hypothesized that those with DKD would be distinguished from DKD resistors by the presence of RAAS activation. METHODS. Renal and systemic hemodynamic function was measured before and after exogenous RAAS stimulation by intravenous infusion of angiotensin II (ANGII) in 75 patients with prolonged T1D durations and in equal numbers of nondiabetic controls. The primary outcome was change in renal vascular resistance (RVR) in response to RAAS stimulation, a measure of endogenous RAAS activation. RESULTS. Those with DKD had less change in RVR following exogenous RAAS stimulation compared with DKD resistors or controls (19%, 29%, 31%, P = 0.008, DKD vs. DKD resistors), reflecting exaggerated endogenous renal RAAS activation. All T1D participants had similar changes in renal efferent arteroilar resistance (9% vs. 13%, P = 0.37) irrespective of DKD status, which reflected less change versus controls (20%, P = 0.03). In contrast, those with DKD exhibited comparatively less change in afferent arteriolar vascular resistance compared with DKD resistors or controls (33%, 48%, 48%, P = 0.031, DKD vs. DKD resistors), indicating higher endogenous RAAS activity. CONCLUSION. In long-standing T1D, the intrarenal RAAS is exaggerated in DKD, which unexpectedly predominates at the afferent rather than the efferent arteriole, stimulating vasoconstriction. FUNDING. JDRF operating grant 17-2013-312.

21 June 2020 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
AWAlanna Weisman
Alanna Weisman
KTKaren Tu
Karen Tu
JYJacqueline Young
Jacqueline Young
MKMatthew Kumar
Matthew Kumar
PAPeter C Austin
Peter C Austin
GBGillian L Booth
Gillian L Booth
Introduction We aimed to develop algorithms distinguishing type 1 diabetes (T1D) from type 2 diabetes in adults ≥18 years old using primary care electronic medical record (EMRPC) and administrative healthcare data from Ontario, Canada, and to estimate T1D prevalence and incidence. Research design and methods The reference population was a random sample of patients with diabetes in EMRPC whose charts were manually abstracted (n=5402). Algorithms were developed using classification trees, random forests, and rule-based methods, using electronic medical record (EMR) data, administrative data, or both. Algorithm performance was assessed in EMRPC. Administrative data algorithms were additionally evaluated using a diabetes clinic registry with endocrinologist-assigned diabetes type (n=29 371). Three algorithms were applied to the Ontario population to evaluate the minimum, moderate and maximum estimates of T1D prevalence and incidence rates between 2010 and 2017, and trends were analyzed using negative binomial regressions. Results Of 5402 individuals with diabetes in EMRPC, 195 had T1D. Sensitivity, specificity, positive predictive value and negative predictive value for the best performing algorithms were 80.6% (75.9–87.2), 99.8% (99.7–100), 94.9% (92.3–98.7), and 99.3% (99.1–99.5) for EMR, 51.3% (44.0–58.5), 99.5% (99.3–99.7), 79.4% (71.2–86.1), and 98.2% (97.8–98.5) for administrative data, and 87.2% (81.7–91.5), 99.9% (99.7–100), 96.6% (92.7–98.7) and 99.5% (99.3–99.7) for combined EMR and administrative data. Administrative data algorithms had similar sensitivity and specificity in the diabetes clinic registry. Of 11 499 711 adults in Ontario in 2017, there were 24 789 (0.22%, minimum estimate) to 102 140 (0.89%, maximum estimate) with T1D. Between 2010 and 2017, the age-standardized and sex-standardized prevalence rates per 1000 person-years increased (minimum estimate 1.7 to 2.56, maximum estimate 7.48 to 9.86, p<0.0001). In contrast, incidence rates decreased (minimum estimate 0.1 to 0.04, maximum estimate 0.47 to 0.09, p<0.0001). Conclusions Primary care EMR and administrative data algorithms performed well in identifying T1D and demonstrated increasing T1D prevalence in Ontario. These algorithms may permit the development of large, population-based cohort studies of T1D.

25 January 2016 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
JBJohnny W. Bai
Johnny W. Bai
GBGeneviève Boulet
Geneviève Boulet
EHElise M. Halpern
Elise M. Halpern
LLLeif Erik Lovblom
Leif Erik Lovblom
DEDevrim Eldelekli
Devrim Eldelekli
BPBruce A. Perkins
Bruce A. Perkins
Older patients with longstanding type 1 diabetes have high cardiovascular disease (CVD) risk such that statin therapy is recommended independent of prior CVD events. We aimed to determine self-reported CVD prevention guideline adherence in patients with longstanding diabetes. 309 Canadians with over 50 years of type 1 diabetes completed a medical questionnaire for presence of lifestyle and pharmacological interventions, stratified into primary or secondary CVD prevention subgroups based on absence or presence of self-reported CVD events, respectively. Associations with statin use were analyzed using multivariable logistic regression. The 309 participants had mean ± SD age 65.7 ± 8.5 years, median diabetes duration 54.0 [IQR 51.0, 59.0] years, and HbA1c of 7.5 ± 1.1 % (58 mmol/mol). 159 (52.7 %) participants reported diet adherence, 296 (95.8 %) smoking avoidance, 217 (70.5 %) physical activity, 218 (71.5 %) renin-angiotensin-system inhibitor use, and 220 (72.1 %) statin use. Physical activity was reported as less common in the secondary prevention subgroup, and current statin use was significantly lower in the primary prevention subgroup (65.5 % vs. 84.8 %, p = 0.0004). In multivariable logistic regression, the odds of statin use was 0.38 [95 % CI 0.15–0.95] in members of the primary compared to the secondary prevention subgroup, adjusting for age, sex, hypertension history, body mass, HbA1c, cholesterol, microvascular complications, acetylsalicylic acid use, and renin-angiotensin system inhibitor use. Despite good self-reported adherence to general CVD prevention guidelines, against the principles of these guidelines we found that statin use was substantially lower in those without CVD history. Interventions are needed to improve statin use in older type 1 diabetes patients without a history of CVD.

8 February 2019 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
AWAlanna Weisman
Alanna Weisman
GTGeorge A. Tomlinson
George A. Tomlinson
LLLorraine L. Lipscombe
Lorraine L. Lipscombe
BPBruce A. Perkins
Bruce A. Perkins
GHGillian A. Hawker
Gillian A. Hawker

10 April 2018 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
YAYaron Arbel
Yaron Arbel
WAWael Abuzeid
Wael Abuzeid
RRRobert S Rosenson
Robert S Rosenson
AWAlanna Weisman
Alanna Weisman
MFMichael E. Farkouh
Michael E. Farkouh